Please activate JavaScript!
Please install Adobe Flash Player, click here for download

ePaper - CCN Ausgabe - Number 2/2012

MAL-019-12-01 Not available for sale in the United States 0124 Mesh Based Protective Systems STEMI patients in 3 Chilean centers, randomized for MGuard (n=20) or a bare metal stent (n=20). Blinded experts performed off-line analysis MICAMI MGuard Trial by Dr. Alejandro Martínez and Dr. Dante Lindefjeld Pontifical Catholic University of Chile, Santiago, Chile 2 30-1 BMSBMS MGuard BMS MGuardMGuard 10% 40% 50% 90% 10% 0% MGuard Randomized Trial: MICAMI MGuard Trial MBG Result in Acute MI Piscione et al.: Multicentre Experience With MGuardTM Net Protective Stent in ST-Elevation Myocardial Infarction: Safety, Feasibility, and Impact on Myocardial Reperfusion.Catheterization and Cardiovascular Interventions 75:715–721 (2010) MGuard, N=89 MACE = Cardiac death, MI, and TLR Multicentre Experience with MGuard: MACE in STEMI 0 6 12 18 24 30 36 0 10 20 30 40 50 MACE% 1 yr 5.6% 2 yrs 7.9% 3 yrs 10.1% Months • MicroNetTM designed to Prevent Distal Embolization • 3 Year MACE Results • Over 800 Patients in Clinical Trials • 1000’s implanted From ESC/EaCtS GUIDELINES "Mesh-based protection may be considered for PCI of highly throbotic or SVG lesions." Class of recommendation - IIb/c Technology Technology Endorsed by ESCby ESC Guidlines